Literature DB >> 30801340

Melanoma With Loss of BAP1 Expression in Patients With No Family History of BAP1-Associated Cancer Susceptibility Syndrome: A Case Series.

Phyu P Aung1, Priyadharsini Nagarajan1, Michael T Tetzlaff2, Jonathan L Curry2,3, Guilin Tang4, Zied Abdullaev5, Svetlana D Pack6, Doina Ivan2,3, Victor G Prieto7,8, Carlos A Torres-Cabala9.   

Abstract

The presence of multiple BAP1-negative melanocytic neoplasms is a hallmark of familial cancer susceptibility syndrome caused by germline mutations in BAP1. Melanocytic tumors lacking BAP1 expression may also present as sporadic lesions in patients lacking a germline BAP1 mutation. Here, we report histomorphologic and clinical characteristics of cutaneous melanomas with loss of BAP1 expression in 4 patients with no known history of BAP1-associated cancer susceptibility syndrome. The lesions were nodular melanomas composed predominantly of intradermal large epithelioid (Spitzoid) melanocytes with nuclear pseudoinclusions as well as scattered multinucleated cells, arising in association with a typical intradermal nevus. Of the 4 patients, only 1 had recurrence. This patient had multiple recurrences with in-transit and regional lymph node metastases. To the best of our knowledge, this is the first reported series of cutaneous melanomas with loss of BAP1 expression arising in patients without a family history of cancer.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30801340      PMCID: PMC8191382          DOI: 10.1097/DAD.0000000000001217

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  14 in total

1.  Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.

Authors:  Jill A Ohar; Mitchell Cheung; Jacqueline Talarchek; Suzanne E Howard; Timothy D Howard; Mary Hesdorffer; Hongzhuang Peng; Frank J Rauscher; Joseph R Testa
Journal:  Cancer Res       Date:  2015-12-30       Impact factor: 12.701

2.  Histomorphologic spectrum of BAP1 negative melanocytic neoplasms in a family with BAP1-associated cancer susceptibility syndrome.

Authors:  Zlatko Marušić; Marija Buljan; Klaus J Busam
Journal:  J Cutan Pathol       Date:  2015-05-12       Impact factor: 1.587

3.  Combined BRAF(V600E)-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevomelanocytes.

Authors:  Klaus J Busam; Joanne Sung; Thomas Wiesner; Andreas von Deimling; Achim Jungbluth
Journal:  Am J Surg Pathol       Date:  2013-02       Impact factor: 6.394

4.  BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.

Authors:  Adriano Piris; Martin C Mihm; Mai P Hoang
Journal:  Hum Pathol       Date:  2014-11-04       Impact factor: 3.466

5.  Germline BAP1 mutations predispose to renal cell carcinomas.

Authors:  Tatiana Popova; Lucie Hebert; Virginie Jacquemin; Sophie Gad; Virginie Caux-Moncoutier; Catherine Dubois-d'Enghien; Bénédicte Richaudeau; Xavier Renaudin; Jason Sellers; André Nicolas; Xavier Sastre-Garau; Laurence Desjardins; Gabor Gyapay; Virginie Raynal; Olga M Sinilnikova; Nadine Andrieu; Elodie Manié; Antoine de Pauw; Paul Gesta; Valérie Bonadona; Christine M Maugard; Clotilde Penet; Marie-Françoise Avril; Emmanuel Barillot; Odile Cabaret; Olivier Delattre; Stéphane Richard; Olivier Caron; Meriem Benfodda; Hui-Han Hu; Nadem Soufir; Brigitte Bressac-de Paillerets; Dominique Stoppa-Lyonnet; Marc-Henri Stern
Journal:  Am J Hum Genet       Date:  2013-05-16       Impact factor: 11.025

6.  BAP1 and cancer.

Authors:  Michele Carbone; Haining Yang; Harvey I Pass; Thomas Krausz; Joseph R Testa; Giovanni Gaudino
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

7.  Ambiguous melanocytic tumors with loss of 3p21.

Authors:  Iwei Yeh; Thaddeus W Mully; Thomas Wiesner; Swapna S Vemula; Sonia A Mirza; Alyssa J Sparatta; Timothy H McCalmont; Boris C Bastian; Philip E LeBoit
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

8.  BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs.

Authors:  Michele Carbone; Laura Korb Ferris; Francine Baumann; Andrea Napolitano; Christopher A Lum; Erin G Flores; Giovanni Gaudino; Amy Powers; Peter Bryant-Greenwood; Thomas Krausz; Elizabeth Hyjek; Rachael Tate; Joseph Friedberg; Tracey Weigel; Harvey I Pass; Haining Yang
Journal:  J Transl Med       Date:  2012-08-30       Impact factor: 5.531

9.  Germline BAP1 mutations predispose to malignant mesothelioma.

Authors:  Joseph R Testa; Mitchell Cheung; Jianming Pei; Jennifer E Below; Yinfei Tan; Eleonora Sementino; Nancy J Cox; A Umran Dogan; Harvey I Pass; Sandra Trusa; Mary Hesdorffer; Masaki Nasu; Amy Powers; Zeyana Rivera; Sabahattin Comertpay; Mika Tanji; Giovanni Gaudino; Haining Yang; Michele Carbone
Journal:  Nat Genet       Date:  2011-08-28       Impact factor: 38.330

10.  Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families.

Authors:  Ching-Ni Jenny Njauw; Ivana Kim; Adriano Piris; Michele Gabree; Michael Taylor; Anne Marie Lane; Margaret M DeAngelis; Evangelos Gragoudas; Lyn M Duncan; Hensin Tsao
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

View more
  2 in total

1.  Novel insights into the BAP1-inactivated melanocytic tumor.

Authors:  Michele Donati; Petr Martinek; Petr Steiner; Petr Grossmann; Tomas Vanecek; Liubov Kastnerova; Isabel Kolm; Martina Baneckova; Pietro Donati; Irina Kletskaya; Antonina Kalmykova; Josef Feit; Petr Blasch; Diana Szilagyi; Alfonso Baldi; Paolo Persichetti; Anna Crescenzi; Michal Michal; Dmitry V Kazakov
Journal:  Mod Pathol       Date:  2021-12-02       Impact factor: 7.842

2.  Gene Expression and Mutational Profile in BAP-1 Inactivated Melanocytic Lesions of Progressive Malignancy from a Patient with Multiple Lesions.

Authors:  Yan Zhou; Andrew C Nelson; Yuyu He; Sarah A Munro; Kyu Young Song; Evidio Domingo-Musibay; Alessio Giubellino
Journal:  Genes (Basel)       Date:  2021-12-22       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.